Waltham: To foster scientific collaboration between the R&D disciplines of drug discovery to the development of special chemical materials, Revvity, Inc. today announced the launch of its Signal Investigation Packagea unified, cloud-native SaaS platform. The new solution from Revvity Signals Software, the IT and software arm of Revvity, will be available worldwide.
The SaaS platform will integrate Revvity Signals Notebook, VitroVivo and Invent applications in a single, robust solution to support the entire drug development process, from early research and in vitro testing and safety to early development, as well as the development of new specialty chemicals.
kevin willoeSenior Vice President and General Manager of Revvity Signals Software, said: “With Signals Research Suite, scientists can further their work with a solution that encapsulates the products they already trust and avoids the complexities and inefficiencies of a fragmented application. focused ecosystem.
Unlike siled point solutions that prevent collaboration and seamless data sharing, Signals Research Suite includes a trio of integrated, scientifically intelligent software applications that serve the entire Do-Test-Decide life cycle.
On top of this, the suite also features advanced analytics, visualizations powered by TIBCO Spotfire, native industry gold standard ChemDraw integration, and a streamlined, modern interface that allows complete control in configuring workflows for a wide range of applications. of techniques, modalities and types of data. interfaces With secure single sign-on access to all applications, as well as centrally located data tutorials, training videos, and software release information, Suite users can spend more time focusing on their experiments instead of switching between independent solutions.
In terms of security and data integrity, Signals Research Suite implements 24/7 global security monitoring, alerting, and escalation by the Revvity Signals Software Security Operations Center. Additionally, by automating routine tasks and workflows, data within the Suite is findable, accessible, interoperable, and reproducible (FAIR), aiding data integrity and regulatory compliance.
For better understanding of data and results, the Suite platform is tailored for both discovery chemical and biological research ideally using cases involving early and late stage in vitro assays, cell line optimization, biological process optimization, in vitro DMPK assays. vitro, animal pharmacokinetic studies, efficacy and safety studies in animals.
Willoe added: “As a group, our commitment has long been to facilitate faster and more efficient communication between scientists by giving them the tools they need to identify critical information in data, share ideas and find information with ease. We believe the name ‘Señales’ embodies this commitment and will continue to guide our work in the future.”
